Horizon Spectra
Built to reveal the biology behind every tumor
Somatic interpretation of tumors that goes beyond variants in isolation characterizing total mutation burden for deeper insight into diagnosis and treatment.
Somatic interpretation of tumors that goes beyond variants in isolation characterizing total mutation burden for deeper insight into diagnosis and treatment.
Cancer genetics, decoded as a whole. Horizon Spectra looks beyond isolated variants, characterizing the full somatic mutation landscape of 26 malignant cancer types to reveal tumor biology, drug response, and progression as one coherent picture.
Horizon implements Association for Molecular Pathology (AMP) somatic tiers across 26 types of malignant cancers, fully compatible with short and long-read, surfacing variant pathogenicity and standard-of-care insight with FDA-approved drugs, plus additional classification tiers for diagnostic and therapeutic insight.
Horizon SeqRx connects genomic findings to therapeutic decisions, pairing somatic variant calls with treatment guidance at the point of care. It dynamically cross-references patient-specific mutations against a vast repository of FDA-approved targeted therapies and actively recruiting global clinical trials.
A clinical-grade interpretation layer for oncologists, pathologists, and translational research programs working across the pan-cancer spectrum.
Spectra scales across sequencing modalities and specimen types, from whole genome sequencing through targeted liquid biopsy.
Comprehensive somatic and germline coverage across the whole genome or exome for the fullest view of tumor biology.
Curated panels spanning major cancer types and their clinically relevant genes.
Cell-free DNA profiling for non-invasive detection and prediction of tumor status.
Bring Spectra into your oncology program and shorten every tumor board decision.
Request access